

June 3, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir/ Madam,

Sub: Press Release - Aurobindo Pharma Inaugurates TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility

We enclose a copy of the Press Release that is being issued by the Company in connection with Inauguration of TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility of Theranym Biologics Private Limited, a subsidiary of the Company.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: as above

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

Hyderabad, India, June 03, 2026

Aurobindo Pharma Inaugurates TheraNym — Pioneering India's Large-Scale Biologics Contract Manufacturing Facility

In the presence of Shri D. Sridhar Babu and Shri Damodar Raja Narasimha, Ministers of the Government of Telangana, Aurobindo Pharma unveiled a landmark CMO that sets a new standard for biologics manufacturing in India — with MSD joining as its anchor customer.

Hyderabad, India — June 03, 2026 — Aurobindo Pharma Limited today marked a significant milestone with the inauguration of TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMO). Ahead of the ceremony, the Directors of Aurobindo Pharma and the senior leadership team of MSD called upon Hon'ble Chief Minister Shri Anumula Revanth Reddy, briefing him on the project and expressing their gratitude for the Government's steadfast support. The TheraNym Biologics facility was then inaugurated by Shri D. Sridhar Babu, Hon'ble Minister for IT, Industries & Commerce and Legislative Affairs of Telangana, and Shri Damodar Raja Narasimha, Minister for Science and Technology of Telangana — a gesture that reaffirms the Government's unwavering commitment to positioning Telangana as a global centre of excellence in pharmaceuticals and biotechnology.

TheraNym represents Aurobindo Pharma's bold and strategic foray into biologics contract manufacturing — a segment that is growing worldwide and is increasingly vital to meeting global demand for biologic therapies.

“TheraNym represents a defining moment in large-scale biologics manufacturing in India and a proud milestone for Aurobindo Pharma. Designed and built to the highest international standards, the facility is positioned to serve the supply chains of leading global pharmaceutical companies. We are privileged to welcome MSD as TheraNym's anchor customer — their confidence in our capabilities is both an honour and a mandate to deliver excellence. As the global biologics market continues its remarkable expansion, TheraNym stands ready to help bring biologic therapies to patients worldwide, reliably and more affordably than before.” — Dr. Satakarni Makkapati, CEO Biologics and Director, Aurobindo Pharma Limited

The facility is strategically located in Borapatla approximately 45 minutes from the Hyderabad's bustling Financial District and is equipped with 15 KL bioreactors, advanced downstream processing suites, aseptic fill-finish capabilities, and quality control laboratories. TheraNym has been designed with international regulatory expectations in mind. The facility is intended to support MSD supply chain, both domestic and export markets, subject to applicable approvals and customer requirements.

“This innovative partnership reflects a shared commitment to strengthening global access to critical biologic medicines. TheraNym adds meaningful capacity and capability to the MSD supply chain, helping enable compliant, and reliable supply of products to the patients who need them most.” - Dr. Dave Maraldo, MSD Executive Vice President and President, MSD Manufacturing Division

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

GRATITUDE TO THE CHIEF MINISTER OF TELANGANA

Aurobindo Pharma extends its deepest gratitude to the Hon'ble Chief Minister of Telangana for meeting with its Directors and taking time to learn about the project. The presence of two Ministers of the Government of Telangana at the inauguration is a further affirmation of the Government's unwavering commitment to the life sciences industry and to positioning Hyderabad as a world-class hub for biopharmaceutical manufacturing.

"The Government of Telangana has been our partner at every step — from policy support to infrastructure facilitation. We are deeply grateful to the Chief Minister for this gesture of solidarity and for championing the cause of Indian pharma on the global stage. We are thankful to Shri. D Sridhar Babu and Shri. Damodar Raja Narasimha for personally gracing the inauguration event.

Building on our aspirational foray into biosimilars with CuraTeQ, Aurobindo is now prioritizing this high-growth segment as a core differentiator — exemplified by the strategic addition of TheraNym Biologics for contract manufacturing." — Mr. Nithyananda Reddy, Vice Chairman and MD, Aurobindo Pharma.

The state Government's Telangana Life Sciences Policy, its investment facilitation through T-Hub and the Telangana State Industrial Infrastructure Corporation (TSIIC), and its proactive engagement with industry bodies have collectively built an ecosystem where companies like Aurobindo Pharma can invest and execute with confidence.

HYDERABAD: INDIA'S BIOTECH CAPITAL

Hyderabad's stature as India's premier pharmaceutical and biotechnology hub is the product of decades of deliberate ecosystem building. The city is home to over 800 pharmaceutical companies, employs more than 300,000 life sciences professionals, and generates pharmaceutical exports exceeding USD 8 billion annually. Genome Valley alone has attracted marquee global and Indian companies and represents one of Asia's densest concentrations of biologics R&D and manufacturing capability.

Key strengths of the Hyderabad ecosystem include:

- World-class scientific talent drawn from IITs, BITS, University of Hyderabad, and the Centre for Cellular and Molecular Biology (CCMB)
- A mature vendor and supplier network for bioprocess equipment, raw materials, and analytical services
- Proximity to international airport enabling rapid logistics for temperature-sensitive biologic products
- A collaborative innovation culture linking industry, academia, and Government through institutions like BIRAC, DBT, and the Telangana Academy for Skill and Knowledge

TheraNym is proud to be a part of this ecosystem and commits to contributing to its further growth through job creation, technology transfer, and supplier development.

INDIA'S POLICY MOMENTUM: A FOUNDATION FOR THE FUTURE

Aurobindo Pharma acknowledges the transformative impact of India's policy landscape in catalysing the growth of domestic biomanufacturing. The Government of India's Production Linked Incentive (PLI) scheme for pharmaceuticals, the National Biopharma Mission, and the Biotechnology Industry Research Assistance Council (BIRAC) are expected to collectively mobilise significant capital and talent into the biologics sector.

Aurobindo Pharma is confident that with sustained Government commitment and support, India can capture a dominant share of the global biologics CDMO market and deliver enormous economic and public health dividends for the nation.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com) is a leading Indian pharmaceutical company with a global footprint spanning over 150 countries. Listed on the NSE and BSE, Aurobindo has built a reputation for quality, scale, and scientific capability across generics, injectables, and increasingly, complex biologics. Through TheraNym, Aurobindo Pharma is charting its next phase of growth as an integrated biologics player and trusted global CMO partner.

For further information or queries, please contact:

Investor Relations | Corporate Communications

Phone: +91 40 66721211

Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com